Upfront lipid-lowering combination therapy in high cardiovascular risk patients: a route to effective atherosclerotic cardiovascular disease prevention
Cardiovascular Research · 2025
DOI: 10.1093/cvr/cvaf045 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Maciej Banach und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Rzgowska 281/289, Lodz 93-228, Poland. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Anticholesteremic Agents, Cholesterol, LDL. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
Despite three decades of using statin therapy, 20 years of experience with ezetimbe, and availability of innovative non-statin lipid lowering therapies (LLT), there are still about 70% patients over the low-density lipoprotein cholesterol (LDL-C) goal, with every 5th to 6th being over the target from the group of very high and extremely high cardiovascular disease (CVD) risk patients. Adding another even every 5th patient at very high CVD risk without any LLT makes this situation highly frustrating, especially lipid disorders are the most common CVD risk factor with the prevalence of over 60%, with the worst awareness within all cardiovascular risk factors (only about 15% people knows their LDL-C level). To answer this since 2021, there is an approach to apply upfront (immediate) lipid-lowering combination therapy of statin and ezetimibe in very high and extremely high-risk patients to be on the LDL-C target as low as possible, but especially as early as possible, enabling to introduce the third line therapy (i.e. bempedoic acid and/or PCSK9 targeted therapy) already after 4–6 weeks. This review discusses the current stage of knowledge and recent data on the group of patients that might benefit the most from the upfront combination LLT, when it should be optimally implemented, and the recent data on its role on LDL-C reduction, cardiovascular and mortality outcomes as well as safety issues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Rzgowska 281/289, Lodz 93-228, Poland.
- Faculty of Medicine, the John Paul II Catholic University of Lublin, Lublin, Poland.
- Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.
- Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice 40-752, Poland.
- Center for Medical Genomics OMICRON, Jagiellonian University Medical College, Krakow, Poland.
ORCID-Profile: Maciej Banach
Zitieren
APA
Banach, M., Surma, S., Guzik, T. J., Penson, P. E., Blaha, M. J., Pinto, F. J., & Sperling, L. S. (2025). Upfront lipid-lowering combination therapy in high cardiovascular risk patients: a route to effective atherosclerotic cardiovascular disease prevention. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf045
Vancouver
Banach M, Surma S, Guzik TJ, Penson PE, Blaha MJ, Pinto FJ, et al. Upfront lipid-lowering combination therapy in high cardiovascular risk patients: a route to effective atherosclerotic cardiovascular disease prevention. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf045
BibTeX
@article{Banach2025,
author = {Banach, Maciej and Surma, Stanisław and Guzik, Tomasz J and Penson, Peter E and Blaha, Michael J and Pinto, Fausto J and Sperling, Laurence S},
title = {Upfront lipid-lowering combination therapy in high cardiovascular risk patients: a route to effective atherosclerotic cardiovascular disease prevention},
journal = {Cardiovascular Research},
year = {2025},
doi = {10.1093/cvr/cvaf045}
}
EUVIMED